Vyome (NASDAQ:HIND) Announces Quarterly Earnings Results

Vyome (NASDAQ:HIND) issued its quarterly earnings results on Wednesday. The company reported ($0.10) EPS for the quarter, Zacks reports.

Vyome Price Performance

Shares of NASDAQ HIND traded down $0.03 during mid-day trading on Wednesday, reaching $2.22. The company’s stock had a trading volume of 11,490 shares, compared to its average volume of 360,629. The firm has a market capitalization of $15.58 million, a PE ratio of -0.18 and a beta of 1.48. The stock has a fifty day moving average of $2.17 and a two-hundred day moving average of $2.32. Vyome has a 52 week low of $1.75 and a 52 week high of $18.60.

Institutional Trading of Vyome

A hedge fund recently bought a new position in Vyome stock. Geode Capital Management LLC purchased a new position in Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned 0.21% of Vyome at the end of the most recent reporting period. Institutional investors own 22.06% of the company’s stock.

Analyst Upgrades and Downgrades

HIND has been the subject of a number of recent research reports. Litchfield Hills Research started coverage on Vyome in a research note on Monday, May 4th. They set a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Vyome in a research note on Wednesday, July 29th. Finally, Zacks Research raised shares of Vyome to a “hold” rating in a report on Wednesday, May 6th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Vyome has a consensus rating of “Hold” and an average price target of $15.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.